Combined treatment of CK2 inhibitors and bortezomib causes mitochondrial apoptosis of MM and MCL cells.

<p>JC1 staining and FACS analysis of MM cells (INA-6 or INA-6 cocoltured with HS-5 (A) or MCL cell lines (Jeko-1 or Rec-1)(B) treated with the CK2 inhibitors CX-4945 or K27, bortezomib (BZ in the figure) at different concentrations or the combination of CX-4945 or K27 and bortezomib for 18h. Data represent mean ± SEM of at least three independent experiments. * indicates p< 0.05. ♦ indicates p<0.05 between samples treated with bortezomib alone (at the dose indicated in figure) and bortezomib together with CX-4945. # indicates p<0.05 between samples treated with bortezomib 15 nM alone and bortezomib 15 nM together with K27 or CX-4945. • indicates p<0.05 between samples treated with bortezomib 25 nM alone and bortezomib 25 nM together with K27 or CX-4945. (C-D) WB analysis for expression of prosurvival signalling proteins (Bcl2, Mcl1) or pro-apoptotic proteins (Bax, Bak) in MM (C) or MCL (D) cell lines treated with the CK2 inhibitors CX-4945 or K27, bortezomib, or the combination of the two compounds for 18h. GAPDH or β-actin was used as a loading control.